HomeInsightsPE

Bafna Pharmaceuticals Ltd P/E Ratio

Bafna Pharmaceuticals Ltd P/E Ratio

download
stocks purchased

₹ 0.0 Cr

Volume transacted

stocks purchased

1.1 K

stocks traded

Last Updated time: 18 Jul 15:30 PM

Image

Bafna Pharmaceuticals Ltd

NSE: BAFNAPH

PE

0

Last updated : 18 Jul 15:30 PM

Key Highlights

    The P/E Ratio of Bafna Pharmaceuticals Ltd is 0 as of 18 Jul 15:30 PM .a1#The P/E Ratio of Bafna Pharmaceuticals Ltd changed from 0 on March 2019 to 0 on March 2020 . This represents a CAGR of 0.0% over 2 years. a1#The Latest Trading Price of Bafna Pharmaceuticals Ltd is ₹ 86 as of 18 Jul 15:30 .a1#The PE Ratio of Pharmaceuticals Industry has changed from 28.5 to 27.2 in 5 years. This represents a CAGR of -0.93%a1# The PE Ratio of Automobile industry is 18.5. The PE Ratio of Finance industry is 24.5. The PE Ratio of IT - Software industry is 29.3. The PE Ratio of Pharmaceuticals industry is 36.7. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 20.5. In 2024a1#The Market Cap of Bafna Pharmaceuticals Ltd changed from ₹ 25.9 crore on March 2019 to ₹ 2.1 crore on March 2020 . This represents a CAGR of -71.53% over 2 years. a1#The Revenue of Bafna Pharmaceuticals Ltd changed from ₹ 18.23 crore to ₹ 41.91 crore over 8 quarters. This represents a CAGR of 51.62% a1#The EBITDA of Bafna Pharmaceuticals Ltd changed from ₹ 2.96 crore to ₹ 3.4 crore over 8 quarters. This represents a CAGR of 7.18% a1#The Net Pr of Bafna Pharmaceuticals Ltd changed from ₹ 1.36 crore to ₹ 1.46 crore over 8 quarters. This represents a CAGR of 3.61% a1#The Dividend Payout of Bafna Pharmaceuticals Ltd changed from 0 % on March 2019 to 0 % on March 2023 . This represents a CAGR of 0.0% over 5 years. a1#

Open Demat Account

Lead form image

Enter your mobile no. to continue

+91

*By signing up you agree to our terms & conditions

50 Years

of Trust & Legacy

₹0 AMC

for First Year

₹0 Brokerage

on Delivery, Intraday, Currency and NSE F&O

×

Historical P/E Ratio of Bafna Pharmaceuticals Ltd

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share. P/E Ratio Formula P/E ratio = (CMP of share/ Earning per share) Types of Price to Earning Ratio 1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance. 2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Historical P/E Ratio of Bafna Pharmaceuticals Ltd

Period
Mar '190
Mar '200

Company Fundamentals for Bafna Pharmaceuticals Ltd

Market Cap

203 Cr

EPS

0.0

P/E Ratio (TTM) *

0.0

P/B Ratio (TTM) *

4.3

Day’s High

86.02

Day’s Low

85.0

DTE *

2.9

ROE *

0.0

52 Week High

116.45

52 Week Low

73.35

ROCE *

0.0

* All values are consolidated

Last Updated time: 18 Jul 15:30 PM

* All values are consolidated

Last Updated time: 18 Jul 15:30 PM

Image

Bafna Pharmaceuticals Ltd

NSE: BAFNAPH

PRICE

86

0.00 (0.00%)

stock direction

Last updated : 18 Jul 15:30

×

PRICE

The current market price or CMP refers to the price at which the securities are trading in the share market. Current price in Over-the-counter costs: The following current price depends upon the bid price & the asking price when a financial asset is sold over-the-counter(OTC). Current Price in Bond Market: The current price of a bond is determined by measuring the actual interest rate against the bid-related interest rate. The par or the face value is then calculated to represent the remaining interest payments due which occur before the maturity of the bond.

Share price Over Time

1M

1Y

3Y

5Y

* All values are in Rupees

SWOT Analysis Of Bafna Pharmaceuticals Ltd

Strength

2

S

Weakness

1

W

Opportunity

0

O

Threats

0

T

Asset Value vs Market Value of Bafna Pharmaceuticals Ltd

Market Value

220

Asset Value

36

5.1 X

Value addition

* All values are in Rupees

Competitive Comparison of P/E Ratio

Company NamePEMarket Cap (INR Cr.)
Bafna Pharmaceuticals Ltd0220
Sun Pharmaceuticals Industries Ltd38382,370
Divis Laboratories Ltd75121,646
Cipla Ltd28121,616
Zydus Lifesciences Ltd30119,269
Dr Reddys Laboratories Ltd20111,194

Key Valuation Metric of Bafna Pharmaceuticals Ltd

Earnings

-7 Cr

0.0 X

PE Ratio

Market Cap

₹220Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

Earnings

-7 Cr

0.0 X

PE Ratio

Market Cap

₹220Cr

PE Ratio

PS Ratio

PB Ratio

The price-to-earnings ratio (P/E ratio) is a valuation measure calculated by dividing a company's current share price by its earnings per share.


P/E Ratio Formula


P/E ratio = (CMP of share/ Earning per share)


Types of Price to Earning Ratio


1. Forward P/E ratio: It is calculated by simply dividing the price of a single unit of a company along with the estimated earnings of a company derived from its future earning guidance.
2. Trailing P/E ratio: It is the most common metric used by investors where past earnings of a company over a period are considered.

PE Ratio of Pharmaceuticals Industry over time

PE Ratio of Top Sectors

×

Historical Market Cap of Bafna Pharmaceuticals Ltd

Market Cap or market capitalisation refers to metrics that are used to measure a company's size. It is defined as the total market value of a company's outstanding shares of stock. Formula of Market Cap: Market Capital = N * P Here, N for the outstanding shares P refers to the closing price of the company's shares. Types of Companies based on Market Cap: - Small-Cap stocks: Up to 500 Crore - Mid-Cap Stocks: From Rs.500 crore up to Rs.7,000 crore - Large-Cap Stocks: From Rs.7,000 crore up to Rs.20,000 crore

Historical Market Cap of Bafna Pharmaceuticals Ltd

Period
Mar '1926
Mar '202

* All values are a in crore

×

Historical Revenue of Bafna Pharmaceuticals Ltd

Revenue term means the amount of money a company earns from its primary business activities such as the sales of its products & services. Types of Revenue: 1. Operating revenue: It refers to the income generated from the core business activities, which are sales of goods or services rendered. 2. Non-Operating revenue: It is the income generated from secondary sources unrelated to the primary business. Examples include rents, dividends, interest, and royalty fees. Formula for Revenue: The formula for calculating revenue is based on two goods & services: For goods: Revenue = Avg unit price x Number of Units sold For services: Revenue = Avg unit price x Number of Customers served.

Historical Revenue of Bafna Pharmaceuticals Ltd

Period
Jun '2218
Sep '2223
Dec '2236
Mar '2343
Jun '2344
Sep '2341
Dec '2329
Mar '2442

* All values are a in crore

×

Historical EBITDA of Bafna Pharmaceuticals Ltd

PBIDT stands for Profit Before Interest, Depreciation, and Taxes. It is a financial metric that measures a company's profitability before accounting for interest expenses, depreciation of assets, and taxes. Formula to calculate PBIDT: PBIDT = Net Income + Interest + Depreciation + Taxes or PBIDT = Operating Income + Depreciation + Taxes PBIDT vs EBITDA vs EBIT vs EBT: Here is a brief explanation of the differences: - PBIDT (Profit Before Interest, Depreciation, and Taxes) includes taxes in its calculation, unlike EBITDA. - EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) excludes taxes and interest, focusing on operational performance. - EBIT (Earnings Before Interest and Taxes) excludes interest and taxes, providing a measure of core operational profitability. - EBT (Earnings Before Taxes) includes all operating income but does not account for interest expenses. Conclusion: PBIDT, similar to EBITDA, is a measure of operational profitability but includes taxes in its calculation.

Historical EBITDA of Bafna Pharmaceuticals Ltd

Period
Jun '223
Sep '223
Dec '225
Mar '238
Jun '238
Sep '234
Dec '23-1
Mar '243

* All values are a in crore

×

Historical Net Profit of Bafna Pharmaceuticals Ltd

Net profit is the amount of money a company retains after accounting for all expenses, depreciation, interest, taxes, and other deductions. Net Profit formula is expressed as: Net Profit = Total Revenue - Total Expense Net Profit Margin Ratio: Net Profit Margin Ratio = Net Profit / Total Revenue

Historical Net Profit of Bafna Pharmaceuticals Ltd

Period
Jun '221
Sep '222
Dec '223
Mar '235
Jun '236
Sep '232
Dec '23-3
Mar '241

* All values are a in crore

×

Historical Dividend Payout of Bafna Pharmaceuticals Ltd

Dividend payout refers to the total dividends paid to shareholders relative to the company's earnings. It is a financial measure that determines the percentage of earnings paid out to existing shareholders as dividends. How to calculate Dividend Payout Ratio? The dividend payout ratio formula is as follows: DPR = Dividends paid / Net earnings With the dividend payout ratio, you can understand the company's priorities. It is an important metric that allows you to easily check DPR online.

Historical Dividend Payout of Bafna Pharmaceuticals Ltd

Period
Mar '190
Mar '200
Mar '210
Mar '220
Mar '230

* All values are a in %

About Bafna Pharmaceuticals Ltd

About Bafna Pharmaceuticals Ltd

    Bafna Pharmaceuticals Limited (BPL) was started as a proprietary concern in 1981 by Mr. Bafna Mahaveer Chand in the name of Bafna Pharmaceutical and has been engaged in the business of manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. The first manufacturing unit was set up at Madhavaram (Chennai) during October 1984 for manufacture of tablets with an installed capacity of 420 lacs tablets p.a. Subsequently the capsule line was added during 1987 with a capacity of 300 lacs capsule p.a. and then liquid line with an installed capacity of 45000 lts p.a was added in 1990. Bafna Pharmaceuticals, incorporated in 1995, had acquired the entire business of the proprietary concern. During the year 2001, the company constructed a separate block at Madhavaram for manufacturing Betalactum products. During 2006, Bafna has set up a 100% EOU unit at Madhavaram for the production of tablets and capsule with a capacity of 6973.20 lacs and 2462.40 lacs. This facility has been set up as per revised Schedule M under the Drugs and Cosmetics Act, 1947. The unit has been WHO GMP certified and also ISO 9000 certified. The manufactured products in this factory catered to the markets of Srilanka, Ghana and Ukraine. Bafna was carrying on contract manufacturing for M/s Croslands Pvt. Ltd, a Mumbai based Pharmaceutical Company during the period 1994 to 2000. The company's first product was registered in Srilanka in 1995 and the company made its first export during the same year. Presently around 57 products of the company are registered in Srilanka. During the year 2000 Bafna registered 3 of its products in Lao and in the year 2006, 4 products were registered in Ukraine. During 2007, Bafna registered 1 product in Ghana. The products registered by the company cover all the therapeutic segments. In the year 2003, the Government of India granted the Export House status to the company. The company received the Best Supplier award from the Srilankan Government during 2005. After establishing itself in the non -regulated market, the company decided to enter into a more lucrative and regulated market of Europe. Towards this objective, the company started construction of a new state of art facility at Grantlayon village, near Red hills, Chennai for the manufacture of Non Betalactum products in solid oral dosage form during 2005. This unit is a 100% EOU unit. The factory was completed and inaugurated on October 2, 2006. This new plant has been set up with guidelines as laid down in European GMP. The machineries installed in the new facility of the company are Programmable Logic Controller and all the contact parts are made of stainless steel. This leads to consistent quality of products produced with no contamination. The Auto Coater machinery used in the unit is imported from Korea and Camera system for detection of unfilled product is imported from USA. The company has entered into an agreement with an UK based company Somex Pharma for sale of cholesterol lowering agent products to be manufactured by Bafna at this unit. A full-scale commercial production would be commenced in the new unit once approval of MHRA is received. Presently company is validating the equipments and process at this unit and taking validation batches for trail run. The Company launched 'Raricap? to domestic market in FY 12. It again launched three more brands namely BSF (Dietary Supplement), Molev (Antiasthamics) and Lopih (Lowering pregnancy induced hypertension) segments for women wellness. In 2022, it expanded operations and set up manufacturing facilities in Chennai, India, with UK-MHRA & TGA- Australia accreditations, with round the year exports to prestigious Regulated Markets and Emerging markets.

Bafna Pharmaceuticals Ltd News Hub

News

Bafna Pharmaceuticals to hold board meeting

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 M...

Read more

28 May 202413:49

News

Bafna Pharmaceuticals to declare Quarterly Result

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 12 F...

Read more

03 Feb 202414:11

News

Bafna Pharmaceuticals announces board meeting date

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 No...

Read more

01 Nov 202317:06

News

Bafna Pharmaceuticals to hold AGM

Bafna Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will ...

Read more

16 Aug 202316:10

News

Bafna Pharmaceuticals schedules board meeting

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 11 A...

Read more

07 Aug 202315:04

News

Bafna Pharmaceuticals to hold board meeting

Bafna Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 26 J...

Read more

23 Jun 202314:04

Product Composition by Percentage (Revenue)

FAQs for PE of Bafna Pharmaceuticals Ltd

What is Bafna Pharmaceuticals Ltd current share price?

The current market price of Bafna Pharmaceuticals Ltd as of July 18, 2024 is ₹86.00.

What is Bafna Pharmaceuticals Ltd's market cap?

Bafna Pharmaceuticals Ltd's market capitalisation stood at ₹220 Cr as of July 18, 2024

What are Bafna Pharmaceuticals Ltd's total net assets?

According to Bafna Pharmaceuticals Ltd's most recent financial filings, the company's net assets total ₹36.1 Cr.

Is Bafna Pharmaceuticals Ltd making a profit or loss?

Bafna Pharmaceuticals Ltd's net Profit as of July 18, 2024 is close to ₹-7 Cr.
up arrow
50yearstrust

Unlimited trading at just

Rs. 399

Rs. 199